Huangming Hong

机构：University of Electronic Science and Technology of China, Sichuan Cancer Hospital · ORCID：0000-0002-0803-1077

发表论文 118 篇 · 总被引 1589 次 · h-index 16

代表论文

• Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial (2025 · Journal of Clinical Oncology · 被引 24)
• Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application (2024 · Molecular Cancer · 被引 18)
• Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression (2024 · Genome Medicine · 被引 15)
• Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy (2025 · Journal of Colloid and Interface Science · 被引 8)
• Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma (2024 · Leukemia · 被引 7)
• Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 6)